pay $45 million upfront, with the deal being worth up to another $1.7 billion. 2016. In September, the company announced it would purchase the rights to Boehringer Ingelheims Phase I bispecific T-cell engager compound (BI 836909, now AMG 420) for use in the treatment of multiple myeloma. 2017. Cash returned to shareholders totalled a record $6.5 billion through dividends and share repurchases. 2018. Amgen was ranked 123 on the Fortune 500 list of the largest United States corporations by revenue. 2019. Amgen announced it would acquire Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to enhance its drug discovery capabilities. In August the company announced it would acquire the Otezla drug programme from Celgene for $13.4 billion, as part of Celgene and Bristol-Myers Squibbs merger deal. In October, Amgen announced it would be acquiring a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. In November, Amgen awarded a $2 million grant to the CDC Foundation to launch the latter's EmPOWERED Health Program, promoting patient engagement in decision making for their cancer treatment. 2021. In March, the company announced it would acquire Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion and Rodeo Therapeutics for up to $720 million. In July, Amgen acquired Teneobio for $900 million. 2022. In August, the company agreed to acquire ChemoCentryx for $3.7 billion in an all-cash deal. ChemoCentryx is the maker of Tavneos—a drug treatment for rare diseases called anti-neutrophil cytoplasmic autoantibody-associated vasculitis—which was approved last year. In December, the company announced it would acquire Horizon Therapeutics for $27.8 billion ($116.50 in cash for each Horizon share, a 20% premium) expanding its rare disease treatments. Acquisition history Amgen (Founded 1983 as Applied Molecular Genetics) Synergen Inc (Acq 1994) Kinetix Pharmaceuticals Inc (Acq 2000) Immunex Corporation (Acq 2002) Tularik Inc (Acq 2004) Abgenix Inc (Acq 2006) Avidia Inc (Acq 2006) Alantos Pharmaceuticals (Acq 2007) Ilypsa Inc (Acq 2007) BioVex Group Inc (Acq 2011) Micromet Inc (Acq 2012) Mustafa Nevzat İlaç (Acq 2012) KAI Pharmaceuticals (Acq 2012) deCODE genetics (Acq 2012) Onyx Pharmaceuticals (Acq 2013) NextCODE genetics (Spun off 2013) Dezima Pharma (Acq 2015) Catherex (Acq 2015) Nuevolution AB (Acq 2019) Otezla (Acq 2019) Five Prime Therapeutics (Acq 2021) Rodeo Therapeutics (Acq 2021) Teneobio (Acq 2021) ChemoCentryx (Acq 2022) Horizon Therapeutics (Acq announced 2022) Vidara Therapeutics International (Acq 2014) Hyperion Therapeutics (Acq 2015) Crealta Holdings (Acq 2015) Raptor Pharmaceutical (Acq 2016) River Vision